地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:15172469628
邮箱:sales@amyjet.com

Alomone Labs公司是一家位于耶路撒冷的以色列著名的生物科技公司,专著于提供生命科学细胞生物学试剂和服务。Alomone 公司作为世界上最著名的离子通道专业供应商,它的离子通道抗体是世界上最全的、质量也非常好,目前被世界各地的科学家广泛的使用。
Alomone Labs is a leading supplier of Ion Channel, GPCR and Neural Signaling tools. We specialize in the design and production of high quality primary antibodies, small molecules, peptide toxins, and proteins. Established in 1989, Alomone Labs has become the most comprehensive source of ion channel research tools used by scientists worldwide.
Alomone Labs公司的产品包括:
Ion Channels
G-Protein Coupled Receptors
Transporters, Exchangers and Pumps
Neurotrophic Factors and Receptors
Neural Signaling
Neural Stem Cells
Cell Imaging Tools
Immuno-Colocalization Products
Live Cell Imaging Products
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Alomone Labs"> Alomone Labs
<艾美捷科技代理visikol品牌全系列产品
Visikol是一家合同研究服务公司,专门从事先进的细胞培养检测和先进的组织成像。自 2016 年成立以来,Visikol开发了一系列组织成像和细胞培养工具,已被所有 20 家前 20 家制药公司和 1,000 多个研究实验室使用。Visikol专注于通过为制药和生物技术公司提供先进的成像和细胞培养工具来加速药物发现和开发过程。这些工具确保药物在发现过程中更快地失败,并且研究人员可以回答更复杂的研究问题,为他们的项目提供信息。Visikol公司的产品线包括:Visikol HISTO组织透明化、Visikol HISTO-M 用于 3D 细胞模型、Visikol® 用于植物生物学™、HUREL产品、辅料。

▍visikol公司产品线
● Visikol HISTO组织透明化:Visikol HISTO通过将组织清除与荧光蛋白和/或免疫荧光相结合,使研究人员能够轻松地以3D方式可视化生物组织。具有以下优势:
1)无损技术:保持组织的完整性和自然结构。
2)快速高效:加速了组织清除和成像的过程。
3)易于使用:简化了复杂的组织清除步骤,使更多研究人员能够轻松掌握。
● Visikol HISTO-M 用于3D细胞培养模型:3D细胞培养模型因其能够更好地模拟体内环境而在药物发现领域得到广泛应用。具有以下功能与特点:
1)组织透明化:Visikol HISTO-M是一种专为3D细胞培养模型和基于板的高通量处理而设计的组织透明化技术。
2)成像与分析:当与荧光标记(如荧光蛋白、免疫荧光、化学染料)和高内涵共聚焦显微镜配合使用时,Visikol HISTO-M可以实现完整的3D细胞培养模型表征和更准确的药物筛选。
● Visikol for Plant Biology:旨在直接替代Hertwig的解决方案,用于使植物组织透明以供显微镜检查。使用100mL Visikol,可以清除多达500张显微镜载玻片上的植物组织。具有以下优势:
1)高效便捷:提高了植物组织透明的效率,简化了实验步骤。
2)广泛应用:适用于各种植物生物学研究,为科研人员提供了有力的工具。
● HUREL 产品:除了提供肝脏模型外,HUREL还提供一系列体外和3D细胞培养检测服务,包括高内涵筛选、血脑屏障通透性、细胞增殖、癌症相关检测(如抗增殖测定、细胞毒性测定、免疫细胞浸润等)、毒性和安全性评估(如肝、脂肪变性和磷脂沉着症、细胞活力和细胞毒性、毒性、划痕/伤口愈合测定等)。此外,HUREL还提供CLEARED TISSUE 3D成像和分析服务、图像和载玻片分析、数字病理学等高级服务。HUREL 产品具有以下特点:
1)代谢能力卓越: HUREL Micro Liver 的代谢能力部分源于其肝细胞数量增加数倍,因此微量滴定孔内的细胞密度更高。HUREL 能够为 DMPK(药物代谢与药代动力学)研究提供卓越的翻译预测性数据。
2)表型稳定持久:HUREL 微肝具有坚如磐石、持久的表型稳定性,为卓越的代谢能力奠定了基础。将 HUREL平台上生成的数据与悬浮液、单一培养、微图案阵列和 3D 球体培养的原代肝细胞的数据区分开来,进一步证明了其稳定性。
3)同行评审和验证:HUREL 微肝模型已被世界领先的制药公司在数十篇出版物中使用,并且是许多合同研究组织服务不可或缺的一部分。
4)多种肝脏模型物种:包括 HUREL猫、HUREL狗、HUREL人类、HUREL迷你猪等,以及 HUREL灵长类动物、HUREL兔、HUREL大鼠 SD、HUREL大鼠 WH、HUREL 动物板等,以满足不同研究需求。
▍visikol产品列表
<| 品名 | 货号 | Categories | 规格 |
| Visikol® HISTO™ Starter Kit | HSK-1 | HISTO products, Kits, Tissue Clearing | - |
| Visikol® HISTO-1™ | H1-30/H1-100 | HISTO products, Tissue Clearing | 30 ml; 100 ml |
| Visikol® HISTO-2™ | H2-30/H2-100 | HISTO products, Tissue Clearing | 30 ml; 100 ml |
| Visikol® HISTO-1™ and Visikol® HISTO-2™ Combo | HH-10/HH-30/HH-100 | HISTO products, Tissue Clearing | 10 ml; 30 ml; 100 ml |
| Visikol® HISTO-M™ Starter Kit | HMSK-1 | HISTO-M for 3D Cell Culture Models, Kits, Tissue Clearing | - |
| Visikol® HISTO-M™ | HM-30/HM-100 | HISTO-M for 3D Cell Culture Models, Tissue Clearing | 30 ml; 100 ml |
| Visikol® for Plant Biology™ | OV-05/OV-15/OV-30/OV-100 | Tissue Clearing, Visikol for Plant Biology | 5 ml; 15 ml; 30 ml; 100 ml |
| Visikol® HISTO™ Buffer Kit | HSB-BK | Buffers, Kits | - |
| Visikol® HISTO™ Washing Buffer 10X | HSK-WB-70/HSK-WB-200 | Buffers | 70 ml; 200 ml |
| Visikol® HISTO™ Permeabilization Buffer | HSK-PMB-30/HSK-PMB-100 | Buffers | 30 ml; 100 ml |
| Visikol® HISTO™ Penetration Buffer | HSK-PB-30/HSK-PB-100 | Buffers | 30 ml; 100 ml |
| Visikol® HISTO™ Blocking Buffer | HSK-BB-30/HSK-BB-100 | Buffers | 30 ml; 100 ml |
| Visikol® HISTO™ Antibody Buffer | HSK-AB-30/HSK-AB-100 | Buffers | 30 ml; 100 ml |
| Dog Brain Slicer | BSDC-2 | Accessories | 2 mm Coronal |
| Ferret Brain Slicer | BSFC-2/BSFS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Gerbil Brain Slicer | BSGC-2/BSGS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Guinea Pig Brain Slicer | BSGPC-2/BSGPS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Piglet Brain Slicer | BSPC-2 | Accessories | 2mm Slots Piglet |
| Rabbit Brain Slicer | BSRBC-2/BSRBS-2 | Accessories | 2 mm Coronal; 2 mm Sagittal |
| Rat Brain Slicer | 多货号 | Accessories | 多规格 |
| Tissue Slicers | 多货号 | Accessories | 多规格 |
| Two Chambered Dipping Objective Cuvette | DOC-2 | Accessories | - |
| ClearWell™ Silicon Imaging Chambers – Pack of 6 | CW0.75/CW1.75/CW3.5/CW7 | Accessories | 0.75 mm; 1.75 mm; 3.5 mm; 7 mm |
| Mouse Brain Slicer | BSLM-2/BSLM-1/BSLC-1/BSLS-1 | Accessories | 1 mm Coronal/1 mm Sagittal/2 mm Coronal/2 mm Sagittal |
<艾美捷科技代理Nanosoftpolymers品牌全系列产品
Nanosoft Polymers(NSP)是一家专注于提供用于治疗、设备和诊断的即用型功能化聚合物和共聚物的企业,旨在弥合聚合物和药物递送之间的差距。NSP生产和销售一系列独特的功能性聚合物、共聚物和聚合物偶联物,其聚合物目录丰富多样,涵盖功能性PLGA - PEG、PLA - PEG、PCL - PEG、脂质PEG、聚(L - 赖氨酸)- PEG、聚(L - 谷氨酸)- PEG和聚乙二醇化试剂等。这些产品可应用于药物/基因递送、封装、细胞粘附和表面修饰等多个研究领域。除了销售现有产品,NSP还专门从事聚合物合成和功能化、纳米颗粒制造、表面改性以及具有广泛分子量范围的反应性低聚物和聚合物的定制合成,能够满足客户多样化的需求。

▍Nanosoftpolymers产品线
● 多糖:是由长链单糖单元通过糖苷键连接而成的高分子碳水化合物,具有良好的生物相容性、无毒性和非免疫原性。
● 抗癌试剂与原料药:提供种类丰富的高品质抗癌试剂与原料药,用于药物研发。
● 脂质:NSP的功能性脂质用于制备脂质体或纳米颗粒,这些脂质体或纳米颗粒可通过脂质头部的官能团进一步进行生物偶联修饰。
● PEI-PEGs:NSP 的 PEI-PEG 聚合物包括 PEG 接枝的支链 PEI和 PEG 偶联的线性PEI,可用于体外和体内将寡核苷酸递送至细胞和组织。
● 聚氨基酸:可提高药物结合物的溶解度和稳定性、药物包封、药物靶向、绕过多药耐药因素、对免疫系统的刺激极小、低毒性以及生物可降解性。
● 脂质 - 聚乙二醇(Lipid-PEGs):提供多样化的脂质及磷脂PEG衍生物,广泛应用于药物递送、脂质体 / 胶束形成、小分子和大分子药物制剂以及表面修饰等领域。
● Poly(amino acid)-PEGs:NSP 的 PEG-PAA 包括聚(L - 赖氨酸)-PEG、聚(L - 谷氨酸)-PEG、聚(L - 天冬氨酸)-PEG 及其功能化共聚物。
● 功能性聚乙二醇:提供多种高品质 PEG 试剂,用于聚乙二醇化、药物递送、生物偶联和表面修饰。NSP 的功能性聚乙二醇包括单线性聚乙二醇、同源双功能聚乙二醇、异源双功能聚乙二醇和多臂聚乙二醇。
● 单体:是一种可通过化学方式或超分子方式与其他分子结合,从而形成(超分子)聚合物的分子。
● 聚酯 - 聚乙二醇(Polyester-PEGs):提供基于聚酯的功能性两亲性嵌段共聚物,如聚乳酸 - 聚乙二醇(PLA-PEG)、聚乳酸 - 羟基乙酸共聚物 - 聚乙二醇(PLGA-PEG)、聚己内酯 - 聚乙二醇(PCL-PEG),用于药物递送研究。
● 按官能团分类的聚合物:包括但不限于:胺基、Boc 或 Fmoc 保护的胺基、羧基、马来酰亚胺基、生物素、叠氮基、巯基、酰肼基、炔基、邻吡啶二硫基(OPSS)、活性琥珀酸酯基、乙烯基砜基(VS)、丙烯酸酯基、硝基苯基碳酸酯基(NPC)、二苯并环辛炔基(DBCO)、叶酸基等。
● 荧光聚合物:提供 “即开即用型” 荧光聚合物,研究人员可借助显微镜或 IVIS 成像技术对聚合物及纳米药物进行追踪。NSP的荧光染料包括罗丹明、荧光素、Cy3、Cy5.0、Cy5.5 及 Cy7 等。
▍Nanosoftpolymers部分产品列表
| 品名 | 货号 | 分子量 | 规格 |
| Hyaluronate Amine | 13390 | 5K, 10K, 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Hyaluronate Thiol | 24656 | 5K, 10K, 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Hyaluronic Acid Tetrabutylammonium | 13378 | 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| Methacrylated Hyaluronic Acid (HA-MA) | 13204 | 50 K, 100 K, 1000 K, 1500 K | 100mg, 1g |
| 10-Hydroxycamptothecin | 11999 | 364.35 | 100mg, 500mg, 1g, 5g, 10g |
| 7-Ethyl-10-hydroxycamptothecin | 12007 | 392.4 | 20mg, 100mg, 500mg, 1g |
| Abarelix Acetate | 12014 | 1416.08 | 1mg, 5mg, 10mg, 25mg, 50mg, 100mg |
| Camptothecin | 11992 | 348.35 | 250mg, 500mg, 1g, 5g |
| Cisplatin | 12032 | 300.05 | 100mg, 200mg, 500mg, 1g |
| Cucurbitacin B | 11964 | 558.712 | 5mg, 10mg, 20mg, 50mg, 100mg |
| Cucurbitacin E | 12024 | 556.696 | 1mg, 5mg, 10mg, 25mg |
| Cyclosporine A | 12086 | 1202.61124 | 100mg, 500mg, 1g, 5g, 10g |
| Doxorubicin hydrochloride | 11947 | 579.98 | 50mg, 100mg, 500mg, 1g |
| Irinotecan HCl | 11985 | 677.18 | 20mg, 50mg, 100mg, 500mg |
| Paclitaxel | 11955 | 853.33096 | 50mg, 100mg, 1g, 10g, bulk |
| Topotecan Hydrochloride | 11977 | 457.91 | 20mg, 50mg, 100mg, 500mg |
| β-Lapachone | 12048 | 242.09429 | 10mg, 25mg, 100mg |
| ALC-0315 | 28068 | 766.290 | 50mg, 100mg, 200mg, 1g |
| DLin-KC2-DMA | 27581 | 642.11 | 5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
| DLin-MC3-DMA | 25325 | 642.11 | 50mg, 100mg, 1g, 5g |
| DODAP (18:1) | 26495 | 648.05 | 100mg, 500mg, 1g |
| DODMA | 27967 | 620.104 | 50mg, 100mg, 1g |
| DOTAP (18:1) | 25396 | 698.555 | 100mg, 500mg, 1g |
| DOTMA | 25335 | 670.575 | 50mg, 100mg, 1g |
| DSTAP (18:0) | 26129 | 702.57 | 100mg, 500mg, 1g |
| SM-102 | 27852 | 709.66 | 50mg, 100mg, 200mg, 1g |
| ALC-0315 | 28068 | 766.290 | 50mg, 100mg, 200mg, 1g |
| DLin-KC2-DMA | 27581 | 642.11 | 5mg, 10mg, 25mg, 50mg, 100mg, 200mg |
| DSPC (18:0 PC) | 26737 | 790.145 | 500mg, 1g, 5g |
| DSPE | 13903 | 748.07 | 100mg, 200mg, 500mg, 1g |
| DSPE-Maleimide/DSPE-MAL | 10791 | 898.19 | 50mg, 100mg, 500mg |
| DSTAP (18:0) | 26129 | 702.57 | 100mg, 500mg, 1g |
| SM-102 | 28527 | 709.66 | 50mg, 100mg, 200mg, 1g |

艾美捷科技代理MegaZyme品牌
Megazyme 成立于1988年,位于爱尔兰,是一家全球知名的酶及酶法分析试剂盒的生产厂家,专注于制造和供应高品质和创新的检测试剂盒和生化分析试剂。Megazyme 产品线以其卓越的高纯度酶制剂而闻名,是全球多种碳水化合物及酶底物产品的核心供应商。该公司目前提供了超过70种诊断试剂盒和超过300种其他试剂和底物。
Megazyme产品广泛应用的领域:
1)食品和饮料:用于检测和分析食品中的成分和添加剂。
2)生物燃料:用于生物燃料的开发和生产过程中的质量控制。
3)动物饲料:确保饲料成分的安全和营养价值。
4)葡萄酒和酿造:用于葡萄酒的发酵和质量控制。
5)乳制品和谷类食品:用于乳制品和谷类食品的营养成分分析。

Megazyme产品线包括:
● 检测试剂盒:涵盖膳食纤维、淀粉、糖类、醇类、有机酸、酶活性等领域;
● 高纯度酶制剂与生化底物:生产供应种类繁多的高纯度酶,包括:碳水化合物水解酶、氧化还原酶、蛋白酶 & 脂肪酶以及其他特异性酶。此外,Megazyme还提供各种高纯度的酶作用底物,特别是碳水化合物底物;
● 分析标准品与参比物质:提供与检测试剂盒配套或独立的高纯度、认证的分析标准品,包括分析标准缓冲液,辅助因子与染色剂等;
● 配套仪器与自动化解决方案:Megazyme 也开发或整合了部分专用仪器,用于高通量处理特定检测 (如膳食纤维) 中的复杂步骤。

GATTA quant有限公司成立于2014年,专注于超高分辨系统中探针的研制,使实验快速、简便、准确。这些探针通过使用特殊的纳米结构,即所谓DNA折纸技术精确定位放置染料分子,可使你测定的显微结果达到几纳米的分辨精度。为确保最优效果和性能,公司会根据您的意愿、要求和意图单独设计定制产品。
Gattaquant的主要产品包括:

GATTA-BEADS

GATTA-BEADS W
<<<
GATTA-CELLS:
GATTA-CELLS
GATTA-CELLS NIR

GATTA-SIM NANORULER

GATTA-STED NANORULER:
GATTA-STED NANORULER
GATTA-STED 3D NANORULER

GATTA-CONFOCAL NANORULER
Localization Based:
GATTA-PAINT HIRES
GATTA-PAINT NANORULER
GATTA-PAINT 3D – EXPERT AND ULTIMATE LINE
GATTA-STORM NANORULER

GATTA-AFM:
GATTA-AFM
GATTA-AFM 3D NANORULER

GATTA-GOLD
<<<<
GOLD NANOHELICES (L/R)

DNA-PAINT STARTER KIT
GATTAQUANT PRODUCT LEGACY
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="GATTA quant"> GATTA quant
艾美捷科技代理Seven Hills Bioreagents品牌。
Seven Hills Bioreagents是一家专注于为生物医学研究和诊断领域提供高质量生物试剂的公司,用户涵盖全球的学术研究机构、生物技术公司、制药公司和诊断实验室。包括包括单克隆抗体、多克隆抗体、重组蛋白、ELISA试剂盒、免疫组化试剂等,广泛应用于癌症研究、免疫学、神经科学、传染病研究等领域。Seven Hills Bioreagents公司凭借其高质量的产品和优质的服务,严格遵循ISO 9001等国际标准,确保产品和服务的高质量,已成为生物医学研究和诊断领域的重要供应商,持续为全球科研和诊断行业提供关键支持。
<<< " data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Seven Hills Bioreagents品牌"> 艾美捷科技代理Seven Hills Bioreagents品牌
<艾美捷科技代理Immunologic品牌全系列产品
Immunologic是WellMed旗下的品牌,该品牌自1999年成立以来,已经积累了超过20年的知识和经验。这使得Immunologic在免疫组织化学领域具有深厚的底蕴和专业的技术实力。免疫组织化学是一种灵敏、特异性和经济高效的应用,用于初始化人体组织和细胞中的基因和蛋白质变化。这表明Immunologic的产品在生物医学研究和诊断中具有重要应用价值。Immunologic公司的产品包括:抗体、检测系统、酶作用物、稀释剂、冷冻培养基等。

▍Immunologic公司产品线
● 抗体:大多数抗体是由哺乳动物产生的,例如小鼠或兔子。从这些动物身上分离出来的血液在血清中含有多克隆抗体(与同一抗原结合的多种抗体),现在可以称为抗血清。为了产生对抗原的单个表位具有特异性的抗体,从动物中分离出分泌抗体的淋巴细胞,并通过将它们与癌细胞系融合而永生化,这些融合的细胞称为杂交瘤,并且会在培养物中不断生长和分泌抗体。分离单个杂交瘤细胞产生细胞克隆,这些细胞克隆都产生相同的抗体;这些抗体称为单克隆抗体。
● 检测系统:Immunologic 的 BrightVision 是最新的聚合物标记技术。与传统的基于生物素-链霉亲和素的检测试剂盒相比,这种简单、稳健、易于使用的无生物素检测系统是独一无二的。BrightVision 的优势是:提高灵敏度;更快的响应时间/节省时间;消除亲和素/生物素背景;提高信噪比;更好的信号放大(膜、核或细胞质)
● 酶作用物:免疫学还有一种独特的显色原底物,广泛用于免疫组织化学染色和免疫印迹,即 Bright DAB。该产品采用双组分系统,由液体稳定的 DAB 显色剂和 DAB 底物缓冲液组成。
● 稀释剂:正常抗体稀释剂用于免疫化学程序。抗体可以直接在该试剂中稀释,可以立即使用或储存在冰箱中。
● 冷冻培养基及水封片剂:冷冻培养基 (CryoCompound) 是一种基于水的冷冻组织包埋培养基,旨在支持低温恒温器切片中的组织块。配方可促进快速冷冻、增强切片并在 -20°C 的工作温度下获得一致的结果。水封片剂广泛用于水溶液的盖玻片,是一种非荧光,并具有抗淬灭成分,可增加样品的观察时间。将 Aqua-Poly/Mount 与大多数荧光染料和染色剂一起使用,包括 DAB、碱性磷酸酶、Fast Red、AEC(氨基乙基脲)和各种其他显色剂,以增强和保持荧光强度。它可用于冷冻切片、脂肪染色剂、免疫组织化学和原位杂交的显色剂以及其他需要水溶性封片剂的应用。
▍Immunologic部分产品列表
<| 货号 | 产品描述 | 规格 |
| BD09 | Normal antibody diluent | 125 ml / 500 ml / 1000 ml |
| UD09 | BrightDiluent, green antibody diluent | 125 ml / 500 ml / 1000 ml |
| RAD09 | BrightDiluent, red antibody diluent | 125 ml / 500 ml / 1000 ml |
| BAD09 | BrightDiluent, blue antibody diluent | 125 ml / 500 ml / 1000 ml |
| YAD09 | BrightDiluent, yellow antibody diluent | 125 ml / 500 ml / 1000 ml |
| 1620-C | CRYCOMPOUND CLEAR | 100 ml |
| 1620-B | CRYCOMPOUND BLUE | 100 ml |
| 1620-Y | CRYCOMPOUND YELLOW | 100 ml |
| 1620-G | CRYCOMPOUND GREEN | 100 ml |
| 1620-R | CRYCOMPOUND RED | 100 ml |
| 1620-O | CRYOCOMPOUND ORANGE | 100 ml |
| 1620-MOHS | CRYOCOMPOUND COLOUR KIT | 4x 100 ml |
| 4058 | MOUNTING MEDIA (WATER BASED) | 30 ml |
| 4059 | MOUNTING MEDIA (WATER BASED) | 50 ml |
| HIER-CC | Citrate buffer, Heat-Induced Epitope Retrieval (10x, Tween20) clear | 100 ml, 250 ml, 500 ml, 1000 ml |
| HIER-CR | Citrate buffer, Heat-Induced Epitope Retrieval (10x, Tween20) Red | 100 ml, 250 ml, 500 ml, 1000 ml |
| HIER-TEC | Tris/EDTA, Heat-Induced Epitope Retrieval (10x, Tween20) clear | 100 ml, 250 ml, 500 ml, 1000 ml |
| HIER-TEB | Tris/EDTA, Heat-Induced Epitope Retrieval (10x, Tween20), Blue | 100 ml, 250 ml, 500 ml, 1000 ml |

艾美捷科技代理Biothema品牌。
Biothema是一家专注于酶学和临床诊断的公司,提供高质量的酶制剂和生物化学试剂,广泛应用于临床诊断、食品检测和生物研究。Biothema公司采用先进的生产和纯化技术,确保酶制剂的高纯度和高活性;产品广泛应用于临床诊断、食品检测和生物研究;提供灵活的定制酶制剂和试剂开发服务,满足客户需求。
Biothema公司主要产品与服务包括:
(1)酶制剂:提供多种高纯度的酶制剂,包括氧化酶、脱氢酶和过氧化物酶。
(2)临床诊断试剂:提供用于临床诊断的试剂盒,包括血糖、胆固醇和乳酸检测试剂盒。
(3)生物化学试剂;提供多种生物化学试剂,用于食品检测、环境监测和生物研究。
(4)定制服务:根据客户需求,提供定制化的酶制剂和试剂开发服务。

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://phosphosolutions.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理ReVacc Scientific品牌
ReVacc Scientific为科学发现、临床诊断和疾病治疗提供可靠的病毒学和免疫学产品和服务。
▍ReVacc Scientific公司产品
● 假病毒:带有报告基因(如荧光素酶)的假病毒,为样本高通量筛选提供了高效的解决方案。基于多种技术平台,ReVacc Scientific生产针对冠状病毒、丝状病毒或高致病性禽流感病毒的假病毒。
● 重组蛋白:公司专注于生产带有关键中和表位的蛋白质,这些蛋白质应用在疫苗、诊断和治疗三大重要领域。核心优势有:使用真核表达系统(哺乳/昆虫细胞)确保获得正确的翻译后修饰;生产的蛋白质能正确组装成其天然的多聚体状态(如二聚体、三聚体)。
● 单克隆抗体:大多数抗体具有中和活性,具有阻断病原体感染细胞的能力。
● 检测试剂盒:用于检测人、小鼠或兽医动物样本中的 IgG 或抗原水平,操作简便。
● 克隆工具:一步法高效组装;一分钟高效转化。

▍ReVacc Scientific公司服务
● 样本中和抗体效价评估:在符合生物安全要求的前提下,为您测定样本的中和活性;
● 定制化蛋白生产:根据需求生产携带特定突变的定制化蛋白;
● 定制化假病毒构建:根据需求生产携带特定突变的定制化假型病毒。
● 诊断试剂盒定制开发:根据需求开发定制试剂盒
● 定制化抗体发现:开发了多色表位特异性单细胞分选技术 (MESCS®),并结合重组单克隆抗体技术,从不同物种样本中发掘有价值的抗体。
● 抗体工程化改造:抗体人源化、抗体标记、抗体核苷酸序列测定、抗体同种型转换抗体格式转换以及抗体种属转换。
● 流式细胞分选服务:用于分选具有特定光散射和荧光特性的细胞群。
▍ReVacc Scientific部分产品列表
| 分类 | 品名 | 货号 | 规格 |
| Pseudovirus Reporter | VSV-Pseudovirus_SARS-CoV-2 WT (Wuhan Strain) Spike with luciferase reporter | P14N41 | 200 μl;1000 μl |
| Pseudovirus Reporter | Pseudovirus_RSV Fusion with Luciferase Reporter (A2 strain) | P11A48 | 200 μl;1000 μl |
| Pseudovirus Reporter | Lenti-Pseudovirus_SARS-CoV-2 (Wuhan Strain) Spike with luciferase reporter | O21F29 | 1.1ml;5.5ml |
| Pseudovirus Reporter | VSV-Pseudovirus_MERS-CoV Spike with luciferase reporter | T53L53 | 200 μl;1000 μl |
| Pseudovirus Reporter | VSV-Pseudovirus_SARS-CoV (2003 strain) Spike with luciferase reporter | V44X39 | 200 μl;1000 μl |
| Monoclonal Antibody | Anti-Dengue E Domain III Monoclonal Neutralizing Antibody | K34Q76 | 100 μg;500 μg |
| Monoclonal Antibody | Anti-Ebola Broad Neutralizing Antibody | P5N48 | 100 μg;500 μg |
| Monoclonal Antibody | Anti-HCV E2 Neutralizing Monoclonal Antibody | X81H49 | 100 μg;500 μg |
| Monoclonal Antibody | Anti-Herpes Simplex Virus gD Antibody | Y48B93 | 100 μg;500 μg |
| Monoclonal Antibody | Recombinant Human Anti-hMPV Fusion IgM Antibody | R7V27 | 20 μg;100 μg |
| Monoclonal Antibody | Recombinant Human Anti-hMPV Fusion IgA Antibody | A89X2 | 20 μg;100 μg |
| Recombinant Protein | Dengue virus 1 E protein | R22F8 | 100 μg;500 μg |
| Recombinant Protein | Ebola Sudan GP protein | B78A28 | 100 μg;500 μg |
| Recombinant Protein | Ebola Zaire Makona GP protein | P54P89 | 100 μg;500 μg |
| Recombinant Protein | Herpes simplex virus (HSV) gD protein (Type 1) | L61Q82 | 100 μg;500 μg |
| Recombinant Protein | HIV-1 Trimeric GP140 protein-clade B, YU2 strain | W44H24 | 100 μg;500 μg |
| Test kit | Human Kallikrein 3/PSA Quantitative ELISA (Ultra-sensitive) | S64N86 | 96-well |
| Test kit | Human Anti-Cytomegalovirus gB Protein Antibody IgG Titer Serologic Assay Kit | W19V42 | 96-well |
| Test kit | Human Anti-Dengue Antibody IgG Titer Serologic Assay Kit (E) | P76A64 | 96-well |
| Test kit | Human Anti-Ebola Antibody IgG Titer Serologic Assay Kit (Trimeric GP) | P78G86 | 96-well |
| Test kit | Human Anti-HIV-1 Antibody IgG Titer Serologic Assay Kit (Trimeric GP140) | R29T18 | 96-well |
| Cloning | Seamless Assembly Master Mix (2X) | Q72R56 | 50μl; 250μl;1ml |
| Cloning | One-Minute Competent Cells (Stbl2 similar) | L86Z19 | 8 x 50 μl; 96 x 50 ul |
| Cloning | One-Minute Competent Cells (DH5 Alpha) | L2A1 | 8 x 50 μl; 96 x 50 ul |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18995651644
邮箱:sales@amyjet.com
0.2675